Compare HIFS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIFS | BWAY |
|---|---|---|
| Founded | 1834 | 2003 |
| Country | United States | Israel |
| Employees | 97 | 129 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.1M | 674.2M |
| IPO Year | N/A | N/A |
| Metric | HIFS | BWAY |
|---|---|---|
| Price | $284.79 | $15.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 23.2K | ★ 139.3K |
| Earning Date | 04-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | N/A | $26.21 |
| P/E Ratio | ★ $12.63 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $220.76 | $10.01 |
| 52 Week High | $338.00 | $26.63 |
| Indicator | HIFS | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 43.04 |
| Support Level | $259.41 | $14.56 |
| Resistance Level | $291.91 | $16.63 |
| Average True Range (ATR) | 9.51 | 0.62 |
| MACD | 1.15 | -0.20 |
| Stochastic Oscillator | 79.34 | 21.03 |
Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.